Blog
GLP-1 News & Updates
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
The Dose
Novo Nordisk Reveals Timeline for Generic Semaglutide Availability
Novo Nordisk has disclosed patent expiration dates and authorized generic plans for semaglutide, signaling lower-cost versions could arrive by 2031.
The DoseFDA Clears Higher-Dose Oral Semaglutide for Weight Loss Indication
The FDA has approved Rybelsus at 25 mg and 50 mg doses for chronic weight management, giving patients a pill-based alternative to weekly GLP-1 injections.